Vol. 7, Issue 2, Part I (2025)

Bexagliflozin, a new therapeutic approach for the treatment of type 2 diabetes mellitus (T2DM), has emerged in the form of bexagliflozin, a novel sodium-glucose co-transporter 2 (SGLT2) inhibitor. The objective of this review paper is to offer a thorough examination of the pharmacology of bexagliflozin.
Bexagliflozin's pharmacological action is the selective inhibition of SGLT2 in the proximal renal tubules, which results in improvements to glycaemic control and urine glucose excretion. It differs from conventional antidiabetic drugs in that it works through a different mechanism, which makes it a desirable option for individuals who have not responded well to previous treatments.
Bexagliflozin has been shown in clinical research to be successful in lowering T2DM patients' HbA1c levels, body weight, and blood pressure. Furthermore, studies demonstrating encouraging results have drawn significant attention to its potential cardiovascular and renal benefits. A fair evaluation of the potential benefits and hazards is made possible by this review's analysis of recorded adverse events and exploration of the underlying mechanisms.
In conclusion, bexagliflozin is a useful addition to the arsenal of anti-diabetic medications. Its unique mechanism, along with its proven effectiveness in glucose control and possible cardiovascular advantages, place it in a promising therapeutic position for T2DM patients. To improve patient outcomes, clinicians who prescribe bexagliflozin must be aware of its safety profile and adopt the proper safety measures. Our grasp of its long-term efficacy and safety will keep getting better with more research and practical data.